A novel preliminary metabolomic panel for IHD diagnostics and pathogenesis

S S Markin1, E A Ponomarenko2, Yu A Romashova2

  • 1Institute of Biomedical Chemistry, Moscow, Russia, 119121. phospholipovit@ibmc.msk.ru.

Scientific Reports
|February 1, 2024
PubMed

Insights

This study identifies key blood metabolites for diagnosing ischemic heart disease (IHD) using machine learning. Machine learning models accurately predicted IHD, highlighting specific metabolites for potential diagnostic use.

Area of Science:

  • Biochemistry
  • Computational Biology
  • Cardiology

Background:

  • Cardiovascular disease (CVD) is a leading global cause of mortality, with ischemic heart disease (IHD) accounting for a significant portion.
  • Accurate and early diagnostics for IHD are crucial for effective patient management and improved outcomes.

Purpose of the Study:

  • To investigate the potential of targeted metabolomic profiling combined with machine learning for diagnosing IHD.
  • To identify specific plasma metabolites and metabolic pathways associated with IHD.

Main Methods:

  • Quantitative analysis of 87 endogenous plasma metabolites in 112 subjects (76 IHD patients, 36 controls).
  • Development of a novel age-adjustment correction method for metabolomics data.
  • Application of various machine learning algorithms (logistic regression, SVM, decision trees, random forest, gradient boosting) for IHD diagnostic model development.

Main Results:

  • Identified 36 significantly altered metabolites in IHD patients, including changes in amino acids, acylcarnitines, and tryptophan catabolism pathways.
  • The random forest model achieved the highest diagnostic accuracy with an Area Under the Curve (AUC) of 0.98.
  • Key metabolites such as Norepinephrine, Xanthurenic acid, Serotonin, and Phenylalanine were identified as significant predictors of IHD.

Conclusions:

  • Targeted metabolomic profiling coupled with machine learning offers a promising approach for IHD diagnostics.
  • A panel of identified metabolites may serve as a novel preliminary biomarker for IHD detection.
  • Further validation studies are warranted to confirm the clinical utility of these findings.